Tuberculosis (TB) is a deadly infectious disease.
Every year, over 10 million people develop active TB and 1.4 million die from it.
TB is often thought of as a disease of the past but a recent resurgence and the spread of drug-resistant forms make it very much an issue of the present day and age.
TB occurs in every part of the world, however the vast majority of cases and deaths are in low- and middle-income countries. According to the World Health Organization, in 2019, around two-thirds of all TB cases occurred in just eight countries: India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa.
Though the global death rate from TB dropped more than 40 percent in the years between 1990 and 2011, there are still crucial gaps in coverage and severe shortcomings when it comes to diagnostics and care options.
Furthermore, we are currently seeing an alarming rise in cases of drug-resistant and multidrug-resistant tuberculosis (DR-TB and MDR-TB) that do not respond to the customary first-line drugs.
MSF has been fighting TB for over 30 years. We provide treatment for the disease in many different contexts, from chronic conflict situations, such as Sudan, to vulnerable patients in stable settings such as Uzbekistan and the Russian Federation.
In 2020, MSF started 13,800 people on TB treatment, including 2,100 with drug-resistant TB.
Our work saves lives
Tuberculosis: Key facts
TB DEATHS IN 2020
PEOPLE STARTED ON TB TREATMENT BY MSF IN 2020
PEOPLE STARTED ON DRUG-RESISTANT TB TREATMENT BY MSF IN 2020
TB caused by a bacterium (Mycobacterium tuberculosis) that is spread through the air when infected people cough or sneeze.
The disease most often affects the lungs but it can infect any part of the body, including the bones and the nervous system.
Most people who are exposed to TB never develop symptoms, since the bacteria can live in an inactive form in the body, but if the immune system weakens, such as in malnourished people, people with HIV or the elderly, TB bacteria can become active.
Five to 15 percent of people infected with TB will develop active TB and become contagious at some point in their lives.
Symptoms include a persistent cough, fever, weight loss, chest pain and breathlessness in the lead up to death. TB incidence is much higher and is a leading cause of death among people with HIV.
The research and development (R&D) of new, more effective diagnostic tools and drugs for TB have been severely lacking for decades.
In countries where the disease is most prevalent, diagnosis has depended largely on one archaic test for the last 120 years – smear microscopy, the microscopic examination of sputum, or lung fluid, for the TB bacilli.
The test is only accurate half of the time, even less so for patients who also have HIV.
This means that too many patients start treatment late – if they start it at all.
Children, who often cannot produce sputum, urgently need a new diagnostic tool, especially since they are particularly vulnerable to dying if they develop active TB.
A promising new diagnostic test, Xpert MTB/RIF, was introduced in 2010 and MSF has used it in many of its programmes since. It’s not applicable to all settings, nor is it effective for diagnosing children or patients with TB that occurs outside of the lungs (extra-pulmonary TB), so MSF continues to call for further R&D in diagnostics for TB.
TB is a treatable and curable disease. A course of treatment for uncomplicated TB takes a minimum of six months.
According to the WHO, an estimated 58 million lives were saved through TB diagnosis and treatment between 2000 and 2018.
When patients are resistant to the two most powerful first-line antibiotics (rifampicin and isoniazid), they are considered to have multidrug-resistant (MDR) TB.
MDR-TB is not impossible to treat, but the drug regime is arduous, taking up to two years and causing many side effects. In 2018, it remained a public health crisis and health security threat, with 484,000 new cases with resistance to rifampicin.
Extensively drug-resistant (XDR) TB is identified when resistance to second-line drugs develops on top of MDR-TB. The treatments for XDR-TB are limited.
In many places where we work, supervising all TB patients during their treatment is difficult to impossible. To help patients complete their treatment, MSF has introduced more flexible strategies.
One of these is TB PRACTECAL, a cutting-edge phase II/III clinical research project to find short, tolerable and effective treatments for people with DR-TB.
Seizing upon the opportunity of the first new TB drugs in half a century, MSF has partnered with the London School of Hygiene and Tropical Medicine and other global leaders in medical research, as well as ministries of health in affected countries, to take action.
Together, they share one big goal: to save the lives of hundreds of thousands of people with DR-TB and close the deadly treatment gap that is fuelling the global crisis.
Listen to British doctor Emily Wise discuss her time treating TB in Uzbekistan on the MSF podcast, Everyday Emergency